Scinovex
article Open AccessTop 1% cited

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

Clinical Infectious Diseases · 2008 · Vol. 46(3) · pp. 327–360
Thomas J. WalshElias AnaissieDavid W. DenningRaoul HerbrechtDimitrios P. KontoyiannisKieren A. MarrVicki A. MorrisonBrahm H. SegalWilliam J. SteinbachDavid A. StevensJo‐Anne van BurikJohn R. WingardThomas F. Patterson

Abstract

Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of patients with prolonged neutropenia, advanced HIV infection, and inherited immunodeficiency and patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and/or lung transplantation. This document constitutes the guidelines of the Infectious Diseases Society of America for treatment of aspergillosis and replaces the practice guidelines for Aspergillus published in 2000 The objective of these

Antifungal resistance and susceptibilityFungal Infections and StudiesInfectious Diseases and MycologyMedicineAspergillosisIntensive care medicineFamily medicineImmunology

MeSH terms

Antifungal AgentsAspergillosisAspergillosis, Allergic BronchopulmonaryHumansLung Diseases, Fungal

Funding

  • Amgen
  • Pfizer
  • Astellas Pharma US
  • Gilead Sciences
  • Celgene
  • Enzon Pharmaceuticals
  • Wellcome Trust
  • Astellas Pharma
Citations
2,688
FWCI
121.26
field-weighted impact
References
340
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.